Gadolinium News and Research

RSS

CWRU researcher to customize tobacco mosaic virus to treat human cancers

A Case Western Reserve University researcher has been awarded more than $3 million in federal and foundation grants to turn common plant viruses into cancer sleuths and search-and-destroy emissaries.

10 Mar 2016

Metabolic syndrome treatment benefits MS patients

Oral antidiabetic medications have beneficial anti-inflammatory effects in patients with multiple sclerosis and metabolic syndrome, providing support for a link between metabolism and autoimmunity, researchers report.

9 Mar 2016

Phase III study: Ocrelizumab significantly reduces disease activity in PPMS patients

Ocrelizumab (OCR) is a humanized monoclonal antibody that selectively targets CD20+B cells. In a randomized, double-blind, placebo-controlled Phase III study (ORATORIO), OCR significantly reduced disease activity in patients with primary progressive multiple sclerosis (PPMS).

27 Feb 2016

Promising phase II results for ozanimod in MS

The selective sphingosine 1-phosphate receptor inhibitor ozanimod significantly reduces lesion activity in patients with relapsing-remitting multiple sclerosis, shows a phase II study published in The Lancet Neurology.

17 Feb 2016

Natalizumab shows relapse prevention benefits over fingolimod in MS

Natalizumab may be superior to fingolimod for preventing relapses during the first year of treatment in patients with relapsing–remitting multiple sclerosis, observational study findings show.

4 Feb 2016

Fingolimod trial INFORMS primary progressive MS strategy

Fingolimod is unable to slow disability progression or brain volume loss in patients with primary progressive multiple sclerosis, show the findings of the INFORMS study.

29 Jan 2016

New technique could improve heart scans for patients

A team of Oxford University researchers has developed a technique that could improve heart scans for patients, giving more information about the heart than traditional scans and without any injections, making them safer and faster.

10 Dec 2015

Study explores prevalence of myocardial scars in middle-aged and older population

In a multiethnic, middle-aged and older study population, the prevalence of myocardial scars (evidence of a heart attack) was nearly 8 percent, of which nearly 80 percent were unrecognized by electrocardiography or clinical evaluation, according to a study in the November 10 issue of JAMA.

9 Nov 2015

GATE opens for generic equivalent to glatiramer acetate in MS

Findings from the GATE study have shown equivalent efficacy and tolerability for a generic version of glatiramer acetate to that of the original brand version in the treatment of relapsing–remitting multiple sclerosis.

15 Oct 2015

Phase III studies show Roche's ocrelizumab reduces relapse rate, delays disability progression in MS patients

Three phase III studies being presented at the European Committee for Treatment Research in Multiple Sclerosis congress demonstrate that treating MS with ocrelizumab reduces relapse rate and delay onset of disability progression compared to interferon beta-1a in relapsing forms of MS and disability progression in primary progressive MS compared to placebo.

12 Oct 2015

Agfa HealthCare awarded new three-year DR contract with Premier, Inc.

Agfa HealthCare announced today that it has been awarded a new three-year group purchasing contract with Premier, Inc., a leading healthcare improvement company, to provide its entire product line of digital radiography (DR) solutions to the alliance's approximately 3,600 member hospitals and 120,000 other alternate healthcare sites in the United States.

From Agfa HealthCare 7 Oct 2015

Tiny nanocrystals could be used in advanced medical imaging technologies to light up cancer cells

Researchers in China have developed tiny nanocrystals that could be used in the next generation of medical imaging technologies to light up cancer cells.

20 Aug 2015

New MRI contrast agent detects tiny breast cancer tumors, micrometastases

Researchers at Case Western Reserve University have developed a magnetic resonance imaging (MRI) contrast agent that detects much smaller aggressive breast cancer tumors and micrometastases than current agents can identify.

13 Aug 2015

Agfa HealthCare to launch new mobile DR system with FreeView telescopic column at AHRA 2015

Agfa HealthCare announces today that it will launch its new mobile DR system with FreeView telescopic column at AHRA 2015, the Association for Medical Imaging Management's annual meeting, in Las Vegas, Nevada, July 19-22.

10 Jul 2015

Animal study highlights major safety concern regarding use of MRI contrast agents in patients

New results in animals highlight a major safety concern regarding a class of magnetic resonance imaging (MRI) contrast agents used in millions of patients each year, according to a paper published online by the journal Investigative Radiology.

26 Jun 2015

Study finds direct evidence of gadolinium deposition in neuronal tissues following contrast-enhanced MRI exams

Mayo Clinic research finds direct evidence of gadolinium deposition in neuronal tissues following intravenous administration of gadolinium-based contrast agents used in MRI exams. The findings were recently published online in the journal Radiology.

17 Mar 2015

Stem cell transplants more effective than mitoxantrone drug for people with severe multiple sclerosis

Stem cell transplants may be more effective than the drug mitoxantrone for people with severe cases of multiple sclerosis (MS), according to a new study published in the February 11, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

12 Feb 2015

Promising results for stem cell therapy in MS

Preliminary findings suggest that nonmyeloablative haematopoietic stem cell transplantation may arrest, or even reverse, the progress of disease among patients with relapsing–remitting multiple sclerosis.

28 Jan 2015

Molecular breast imaging: an interview with Jim Calandra, CEO Gamma Medica

Studies have shown that mammograms fail to detect cancers in one-third to one-half of women with dense breasts (Clinical Literature on MBI). In some cases, the findings from a mammogram are inconclusive and secondary screening will almost always be required.

6 Oct 2014

Experimental agent TRO40303 ineffective in patients with heart attack

The administration of an experimental agent known as TRO40303 to patients who have had a heart attack, with the hope of preventing tissue damage when impaired blood flow is corrected (reperfusion), was disappointingly ineffective according to results of a European study of patients with acute ST-elevation myocardial infarction (STEMI) presented today as a Hot Line the ESC Congress 2014 with simultaneous publication in the European Heart Journal.

1 Sep 2014